REVB
NASDAQRevelation Biosciences Inc.
News · 26 weeks34+200%
2026-03-012026-08-23
Mix1990d
- SEC Filings6(32%)
- Market5(26%)
- Insider5(26%)
- Other3(16%)
Latest news
25 items- SECRevelation Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- PRRevelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study– Study on track to begin later this year – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that it has selected Avance Clinical, a full-service contract research organization (CRO) with global operations, to serve as the CRO for its Phase 2/3 adaptive-design TITAN study for evaluating Gemini in patients with acute kidney injury (AKI). The importance of hiring the right CRO is a critical step for a successful study. The CRO manages the nuts and bolts of running the study including such things as site identification and management, patient
- INSIDERChief Financial Officer Zygmont Chester Stanley Iii was granted 208,073 shares, gifted 208,073 shares and received a gift of 208,073 shares (SEC Form 4)4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)
- INSIDERDirector Chawla Lakhmir S was granted 32,011 shares, increasing direct ownership by 263% to 44,169 units (SEC Form 4)4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)
- INSIDERDirector Roper Jess was granted 32,011 shares, increasing direct ownership by 250% to 44,839 units (SEC Form 4)4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)
- INSIDERChief Executive Officer Rolke James was granted 208,076 shares, increasing direct ownership by 97% to 422,814 units (SEC Form 4)4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)
- INSIDERDirector Carver Jennifer was granted 32,011 shares, increasing direct ownership by 251% to 44,769 units (SEC Form 4)4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Revelation Biosciences Inc.SCHEDULE 13G/A - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)
- SECRevelation Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- NEWSRevelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026SAN DIEGO, CA / ACCESS Newswire / August 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three and six months ended June 30, 2026.Corporate HighlightsAnnounced formation of an Acute Kidney Injury Advisory Board for the upcoming Phase 2/3 AKI clinical trial and subsequent expansion of the AKI Advisory BoardContinued progress on Phase 2/3 clinical study start up activitiesReleased results of an independent market assessment that showed a potential $94 billion total addressable market for Gemini"Start-up act
- SECSEC Form 10-Q filed by Revelation Biosciences Inc.10-Q - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- NEWSIndependent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney InjurySAN DIEGO, CA / ACCESS Newswire / August 3, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, announced today results of an independent market assessment which identified a potential $94 billion total addressable market for Gemini, confirming the unmet medical need.The independent market assessment evaluated Gemini for the treatment of Stage 2 and Stage 3 Acute Kidney Injury (AKI), a major cause of morbidity and mortality, which according to publicly available data affects more than 10% of all hospitalized patients and more than 50% of patients admitted
- NEWSRevelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, CA / ACCESS Newswire / July 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that on July 15, 2026, the Compensation Committee of Revelation's Board of Directors approved three inducement grants totaling 108,000 restricted stock units ("RSUs") covering 108,000 shares of the Company's common stock to three newly hired non-executive employees. The inducement grants were granted pursuant to the Revelation Biosciences, Inc. 2026 Equity Inducement Plan ("2026 Inducement Plan"). The awards were granted as a material inducement t
- SECSEC Form 8-A12B filed by Revelation Biosciences Inc.8-A12B - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- SECRevelation Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- NEWSRevelation Biosciences Announces Adoption of Stockholder Rights PlanSAN DIEGO, CA / ACCESS Newswire / July 10, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that its Board of Directors (the "Board") has adopted a stockholder rights plan (the "Rights Plan") and declared a dividend distribution of one right (a "Right") for each outstanding share of the Company's common stock.The Rights Plan was adopted pursuant to a Rights Agreement, dated as of July 10, 2026 (the "Rights Agreement"), between the Company and Continental Stock Transfer & Trust Company, as rights agent. The dividend is payable to stockhol
- SECRevelation Biosciences Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- SECRevelation Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- NEWSRevelation Biosciences Expands Acute Kidney Injury Advisory BoardSAN DIEGO, CA / ACCESS Newswire / June 1, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced the expansion of its Acute Kidney Injury (AKI) Advisory Board, with the addition of two new members, Dr. Peter Pickkers and Dr. Lui Forni, ahead of its upcoming Phase 2/3 clinical trial. The distinguished panel comprises internationally recognized nephrologists and critical care physicians who will guide the company's clinical strategy, monitor trial progress, and advance Gemini as a treatment for AKI. Drawing on their collective expertise, the boa
- SECSEC Form SCHEDULE 13G filed by Revelation Biosciences Inc.SCHEDULE 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)
- SECSEC Form DEF 14A filed by Revelation Biosciences Inc.DEF 14A - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- NEWSRevelation Biosciences, Inc. Releases Corporate Update Letter to StockholdersSAN DIEGO, CA / ACCESS Newswire / May 11, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, released its 2026 annual meeting proxy materials today, which included a corporate update letter to its stockholders from James Rolke, Chief Executive Officer of Revelation, the body of the letter follows.Dear Stockholders:As you know, Revelation is a clinical stage company working to develop a high-impact, potentially lifesaving drug called Gemini for the treatment of acute kidney injury (AKI). While our passionate team is dedicated and hardworking, we couldn't a
- SECRevelation Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- NEWSRevelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026SAN DIEGO, CA / ACCESS Newswire / May 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three months ended March 31, 2026.Corporate HighlightsAnnounced agreement with FDA on a single adaptive Phase 2/3 study for approval of Gemini for treatment of acute kidney injuryReceived net proceeds of $6.7 million from warrant inducement in January 2026Participated in a fireside chat at the 38th Annual ROTH Conference, during which management discussed the Company's developments and strategic prioritiesPresented addit
- SECSEC Form 10-Q filed by Revelation Biosciences Inc.10-Q - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
REVB FAQ
7 questionsWhat does Revelation Biosciences Inc. do?
Revelation Biosciences, Inc., a clinical -stage biopharmaceutical company, focuses on the development or commercialization of innate immune system therapeutics and diagnostics. The company's lead therapeutic candidate is REVTx-99, an anti -viral nasal drop for the prevention or treatment of respiratory viral infections, as well as for the prevention or treatment of nasal congestion due to allergies or chronic rhinosinusitis. Its lead diagnostic is the REVDx -501, a rapid test kit to detect various respiratory viral infections. The company also develops REVTx-200, an intranasal immunomodulator...Where does REVB stock trade?
Revelation Biosciences Inc. (REVB) is listed on NASDAQ.What sector and industry is REVB in?
Revelation Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Revelation Biosciences Inc. go public?
Revelation Biosciences Inc. (REVB) completed its IPO in 2020.What are analysts saying about REVB?
Revelation Biosciences Inc. has had 1 recent analyst action on file. The most recent action was from Roth Capital: Buy with a $1200.00 price target on 2022-02-17. Recent price targets cluster around $1200.00.What companies are similar to REVB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare REVB side-by-side with any of them on Quantisnow.How can I track REVB on Quantisnow?
Quantisnow aggregates Revelation Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow REVB to receive live email and push alerts on every new disclosure.